Waters Corp WAT reported fourth-quarter FY21 revenue growth of 8% year-on-year in CC to $836 million above the consensus of $821 million.
- Sales into the pharmaceutical market increased 8% in CC, sales into the industrial market increased 7% in CC, and sales into the academic and government markets increased 5% in CC.
- Recurring revenues increased 3% in CC, while instrument system sales increased 12% in CC.
- Geographically, sales in Asia increased 9%, sales in the Americas increased 8% (with U.S. sales growing 8%), and sales in Europe increased 1%.
- Non-GAAP EPS of $3.67 beat the consensus of $3.47.
- Waters generated $218 million in operating cash flow.
- Outlook: Waters sees Q1 FY22 revenue of $626.8 million - $639.97 million in CC versus the consensus of $627.1 million. Waters sees non-GAAP EPS of $2.25 - $2.35 below the consensus of $2.38.
- Waters sees FY22 revenue of $2.897 billion - $2.953 billion in CC versus the consensus of $2.92 billion. Waters sees non-GAAP EPS of $11.75 - $12.00 versus the consensus of $11.78.
- Price Action: WAT shares are trading 2.37% higher at $327.71 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in